A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue SUPPL. C, 1996, Pages 103-113

  Zachariah, J ^a  

^a ICON PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SOMNOLENCE; STREPTOCOCCUS PNEUMONIAE; VERTIGO; VOMITING;

EID: 0029830938     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.suppl_c.103     Document Type: Article

References (27)

1. Anthonisen, N. R., Manfreda, J., Warren, C. P. W., Hershfield, E. S., Harding, G. K. M. & Nelson, N. A. (1987). Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 106, 196-204.
2. Baldwin, D. R., Wise, R., Andrews, J. M., Ashby, J. P. & Honeybourne, D. (1990). Azithromycin concentrations at the sites of pulmonary infection. European Respiratory Journal 3, 886-90.
3. Barry, A. L. & Jones, R. N. (1988). Interpretative criteria for the agar diffusion susceptibility test with azithromycin. Journal of Antimicrobial Chemotherapy 22, 637-41.
4. Barry, A. L., Jones, R. N. & Thornsberry, C. (1988). In vitro activities of azithromycin (CP-62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrobial Agents and Chemotherapy 32, 752-4.
5. Barry, A. L., Thornsberry, C., Gavan, T. L. & Collaborative Antimicrobial Susceptibility Testing Group (1989). Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin. European Journal of Clinical Microbiology and Infectious Diseases 8, 544-9.
6. Barsic, B., Schönwald, S., Sagud, M. & Kilnar, I. (1994). Three days azithromycin versus 10 days cefaclor in the treatment of lower respiratory tract infections. In Recent Advances in Chemotherapy (Einhorn, J., Nord, C. E. & Norrby, S. R., Eds). American Society for Microbiology, Washington, DC.
7. Beglhi, G., Vaghi, A., Bemi, F., D'Anto, M., Molino, A., Casalini, A. et al. (1994). Efficacy and tolerability of amoxicillin/clavulanic acid vs azithromycin in acute purulent exacerbation of chronic bronchitis. In Program and Abstracts of Ninth Mediterranean Congress of Chemotherapy, Milan, Italy, 1995. Abstract FS107. Mediterranean Society of Chemotherapy.
8. Bradbury, F., (1993). Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 31, Suppl. E, 153-62.
9. Bright, G. M., Nagel, A. A., Bordner, J., Desai, K. A., Dibrino, J. N., Nowakowska, J. et al. (1988). Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives: a new class of macrolide antibiotics, the azalides. Journal of Antibiotics 41, 1029-47.
10. Cockburn, J., Gibberd, R. W., Reid, A. L. & Sanson-Fisher, R. W. (1987). Determinants of non-compliance with short-term antibiotic regimens. British Medical Journal 295, 814-8,
11. Fiese, E. F. & Steffen, S. H. (1990). Comparison of the acid stability of azithromycin and erythromycin A. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 39-47.
12. Foulds, G. & Johnson, R. B. (1993). Selection of dose regimens of azithromycin. Journal of Antimicrobial Chemotherapy 31, Suppl. E, 39-50.
13. Foulds, G., Shepard, R. M. & Johnson, R. B. (1990). The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 73-82.
14. Greenberg, R. N. (1984). Overview of patient compliance with medication dosing: a literature review. Clinical Therapeutics 6, 592-9.
15. Gwaltney, J. M. (1990). Acute bronchitis. In Principles and Practice of Infectious Diseases, 3rd edn. (Mandell, G. L., Douglas, R. G. & Bennett, J. E., Eds), pp. 529-31. Churchill Livingstone, New York.
16. Hardy, D. J., Hensey, D. M., Beyer, J. M., Vojtko, C., McDonald, E. J. & Fernandes, P. B. (1988). Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrobial Agents and Chemotherapy 32, 1710-9.
17. Hoepelman, A. I. M., Sips, A. P., van Helmond, J. L. M., van Barneveld, P. W. C., Neve, A. J., Zwinkels, M. et al. (1993). A single-blind comparison of a three-day azithromycin and ten-day co-amoxiclav treatment of acute and lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 31, Suppl. E, 147-52.
18. Kronsick, A. (1991). Editorial. Clinical Therapeutics 13, 148.
19. Mertens, J. C. C., van Barneveld, P. W. C., Asin, H. R. G., Ligtvoet, E., Visser, M. R., Branger, T. et al. (1992). Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. Antimicrobial Agents and Chemotherapy 36, 1456-9.
20. Morandini, G., Perduca, M., Zannini, G., Foschino, M. P., Miragliotta, G. & Carnimeo, N. S. (1993). Clinical efficacy of azithromycin in lower respiratory tract infections. Journal of Chemotherapy 5, 32-6.
21. National Committee for Clinical Laboratory Standards (1985). Performance Standards for Antimicrobial Disc Susceptibility Tests; Approved Standard M2-A4. NCCLS, Villanova, PA.
22. Panteix, G., Guillaumond, B., Harf, R., Desbos, A., Sapin, V., Leclercq, M. et al. (1993). In-vitro concentration of azithromycin in human phagocytic cells. Journal of Antimicrobial Chemotherapy 31, Suppl. E, 1-4.
23. Pechère, J.-C. (1993). The use of macrolides in respiratory tract infections. International Journal of Antimicrobial Agents 3, S53-S61.
24. Pilot, M. A. & Qin, X. Y. (1988). Macrolides and gastrointestinal motility. Journal of Antimicrobial Chemotherapy 22, Suppl. B, 201-6.
25. Retsema, J. A., Bergeron, J. M., Girard, D., Milisen, W. B. & Girard, A. E. (1993). Preferential concentration of azithromycin in an infected mouse thigh model. Journal of Antimicrobial Chemotherapy 31, Suppl. E, 5-16.
26. Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G. et al. (1987). Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrobial Agents and Chemotherapy 31, 1939-47.
27. Sevieri, G., Roggi, G. & Monacci, A. (1993). A comparison between amoxycillin/clavulanic acid and azithromycin in exacerbations of chronic bronchitis sustained by Haemophilus influenzae. Minerva Pneumologica 32, 67-70.